Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire...
The initiation biomarker-driven trials have revolutionized oncology drug development by challenging the traditional phased approach and introducing basket studies. Notable successes in non-s...
1. The progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was significant. 2. Grade ≥3 treatment-relat...
Although adjuvant systemic therapy (AT) has demonstrated improved survival in patients with resected non-small cell lung cancer, it remains underutilized. Recent trials demonstrating improve...
Bookmark Click here to read this study in NEJM. VA design by Bryan Sun. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from...
Mutation in KRAS protooncogene represents one of the most common genetic alterations in NSCLC and has posed a great therapeutic challenge over the past ~ 40 years since its discovery. How...
Soluble LAG-3 protein eftilagimod alpha combined with pembrolizumab shows promising clinical efficacy as first-line treatment for advanced or metastatic NSCLC....
Primary care clinicians take a “whole person” approach and are responsible for a wide range of preventive healthcare efforts....
This study has two objectives: first, to explore the diagnostic experiences of black/African American (BAA) patients with lung cancer to pinpoint pitfalls, suboptimal experiences and instanc...
Bookmark Click to read this study in NEJM. VA design by Bryan Sun. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 ...
Selpercatinib doubled progression-free survival, increased response rate, and delayed pulmonary and physical deterioration in RET fusion-positive NSCLC....
Toripalimab added to etoposide plus cisplatin or carboplatin improved survival in extensive-stage small cell lung cancer....
Perioperative chemotherapy plus nivolumab outperforms perioperative chemotherapy alone in patients with resectable non-small cell lung cancer....
The objective of this study was to describe the patterns of failure (POF), frequency of low volume relapse (LVR), and candidacy for further ablative therapy at time of disease progression (P...
The intricate molecular pathways governing cancer development and progression have spurred intensive investigations into novel therapeutic targets. Glycogen Synthase Kinase-3 (GSK3), a compl...
Bookmark1. 4-year event-free survival was significantly greater in I-SABR (77%) versus SABR alone (53%). 2. More patients in the I-SABR group experienced grade 3 immunological adverse events...
Local consolidative therapy (LCT) has emerged as a promising approach for the treatment of oligometastatic non-small cell lung cancer (NSCLC). While stage IV NSCLC was traditionally consider...
The rhythmic expression of the circadian clock is intimately linked to the health status of the body. Disturbed circadian clock rhythms might lead to a wide range of metabolic diseases and e...
A real-world study confirms survival outcomes of atezolizumab plus chemotherapy in extensive-stage small cell lung cancer....
Epigenetic alterations are widespread in cancer and can complement genetic alterations to influence cancer progression and treatment outcome. To determine the potential contribution of DNA m...
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
